National Cardiogenic Shock Initiative: Published Results from CCI

January 26, 2018

Dr. Babar Basir of Henry Ford presents initial results from the National Cardiogenic Shock Initiative. The National CSI is a single-arm, multicenter study to assess the feasibility of whether outcomes in cardiogenic shock can be improved by using standardized best practices including inserting Impella® early and before PCI. Dr. Basir presents results on 41 patients with inclusion and exclusion criteria based on the SHOCK trial, with an additional exclusion criteria of the use of IABP prior to MCS.

The National CSI protocol is based on three best practices:

  • Weaning off of inotropes
  • Placing Impella pre-PCI
  • Use of hemodynamic monitoring for escalation and weaning

Observational data generated from adopting the National CSI shock protocol, which emphasizes the initiation of early MCS with invasive hemodynamic monitoring and rapid door to support times, has shown an association with improved survival in patients who present with AMICS. Results of these 41 patients showed a 76% survival to discharge with 100% native heart recovery in surviving patients.

These results were published in December 2017 with co-authors Drs. Ted Schreiber, Simon Dixon, et. al. in Catheter Cardiovascular Interventions.

Related Content

Subscribe, Tweet this or join the conversation by following us on Twitter: @ProtectedPCI

IMP-481-17

To learn more about the Impella® platform of heart pumps, including important risk and safety information associated with the use of the devices, please visit: www.protectedpci.com/indications-use-safety-information/